Evidence map›Paper›PMID 25819590›Full record

ArticleBritish journal of clinical pharmacology2015

Mirabegron.

Sebastiaan C Goulooze, Adam F Cohen, Robert Rissmann

Abstract read
In one paragraph

Article in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Mechanisms of prostatic inflammation-mediated male lower urinary tract symptoms.American journal of clinical and experimental urology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sebastiaan C GouloozeCentre for Human Drug Research, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-3369-6107
Adam F CohenCentre for Human Drug Research, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-7452-6222
Robert RissmannCentre for Human Drug Research, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mirabegron is used for the treatment of symptoms associated with overactive bladder syndrome. It selectively stimulates the β3 -adrenoreceptor, which relaxes the detrusor muscle. This improves urine storage by distension of the bladder body.

Indexed as

AcetanilidesAdrenergic beta-3 Receptor AgonistsHumansNeuromuscular AgentsThiazolesUrinary BladderUrinary Bladder, OveractiveAcetanilidesAdrenergic beta-3 Receptor AgonistsmirabegronNeuromuscular AgentsThiazoles

Identifiers

PMID25819590
PMCPMC4594713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.